Skip to main content

Table 2 Identification and validation of prognostic transcripts

From: Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients

Gene

MNCs

VLBs

RNAseq (N = 96)

QRT/PCR (N = 67)

RNAseq (N = 96)

QRT/PCR (N = 67)

HR

FDR

HR

P-value

HR

FDR

HR

P-value

CEP70

2.15

0.033

1.14

0.28

2.18

0.018

1.68

< 0.01

COMMD7

3.33

0.082

1.15

0.53

4.27

0.018

1.05

0.76

DNMT3B

1.57

0.076

1.23

0.06

1.61

0.078

1.30

0.05

ECE1

1.78

0.093

1.03

0.80

1.60

0.088

1.32

0.03

LNX2

3.38

0.054

1.10

0.62

3.21

0.078

1.08

0.59

NEGR1

1.64

0.070

1.02

0.74

1.51

0.078

1.07

0.32

PIK3C2B

1.74

0.093

1.06

0.63

1.82

0.088

1.30

0.04

SEMA4D

3.13

0.082

0.95

0.81

2.77

0.088

1.38

0.06

SMAD2

4.50

0.075

0.99

0.95

5.67

0.018

1.07

0.75

TAF8

8.12

0.070

1.12

0.60

8.73

0.058

1.22

0.10

ZNF444

4.14

0.033

1.10

0.18

3.06

0.088

1.05

0.40

  1. MNCs Bulk mononuclear cells, VLBsCD34+ Undifferentiated CD34+ viable blasts, RNAseq RNA sequencing expression results, Q-RT/PCR Quantitative RT/PCR assay expression results, HR Hazard ratio, FDR False discovery rate